Rezolute (RZLT) Cash from Investing Activities (2012 - 2026)
Rezolute's (RZLT) quarterly Cash from Investing Activities came in at $12.3 million in Q1 2026, down 46.73% year-on-year from $23.1 million in Q1 2025, and down 46.17% quarter-over-quarter from $22.8 million in Q4 2025.
Rezolute (RZLT) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Rezolute has disclosed Cash from Investing Activities across 13 years of filings, most recently posting $12.3 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $12.3 million, down 46.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.0 million (down 792.0% YoY), and the FY2025 annual result was -$14.5 million, down 129.86% from the prior year.
- Cash from Investing Activities came in at $12.3 million for Q1 2026 at Rezolute, down from $22.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $23.1 million in Q1 2025 to a low of -$95.0 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is $2.6 million (2023), against an average of -$6.7 million.
- Across the five-year window, Cash from Investing Activities jumped 21497.59% in 2023 and sank 1996.01% in 2024, its largest moves.
- Rezolute's Cash from Investing Activities stood at -$83000.0 in 2022, then surged by 21497.59% to $17.8 million in 2023, then sank by 35.42% to $11.5 million in 2024, then jumped by 98.92% to $22.8 million in 2025, then sank by 46.17% to $12.3 million in 2026.
- The last three Cash from Investing Activities figures came in at $12.3 million (Q1 2026), $22.8 million (Q4 2025), and -$68.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Rezolute | 415.38 Mn | 415.38 Mn | - | 12.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.28 Mn |
| Mar 31, 2026 | 12.28 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Sep 30, 2025 | -68.49 Mn |
| Sep 30, 2025 | -68.49 Mn |
| Jun 30, 2025 | 346,000.00 |
| Jun 30, 2025 | 346,000.00 |
| Mar 31, 2025 | 23.05 Mn |
| Mar 31, 2025 | 23.05 Mn |
| Dec 31, 2024 | 11.47 Mn |
| Dec 31, 2024 | 11.47 Mn |
| Sep 30, 2024 | -49.41 Mn |
| Sep 30, 2024 | -49.41 Mn |
| Jun 30, 2024 | 19.66 Mn |
| Jun 30, 2024 | 19.66 Mn |
| Mar 31, 2024 | 8.67 Mn |
| Mar 31, 2024 | 8.67 Mn |
| Dec 31, 2023 | 17.76 Mn |
| Dec 31, 2023 | 17.76 Mn |